Sugi Predict

Sugi Predict / Targets / CTBP2

CTBP2

C-terminal-binding protein 2 · P56545 · CTBP2 on Sugi Atlas →

7,525 patent compounds predicted against CTBP2, 5,120 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL559795 SCHEMBL559795 0.54 13/20
SCHEMBL559796 SCHEMBL559796 0.54 13/20
SCHEMBL559315 SCHEMBL559315 0.57 9/20
SCHEMBL559316 SCHEMBL559316 0.57 9/20
SCHEMBL194273 SCHEMBL194273 0.65 5/20
SCHEMBL1702738 SCHEMBL1702738 0.53 3/20
SCHEMBL1754977 SCHEMBL1754977 0.53 3/20
SCHEMBL838026 SCHEMBL838026 0.52 3/20
SCHEMBL838027 SCHEMBL838027 0.52 3/20
SCHEMBL405392 SCHEMBL405392 0.44 3/20
SCHEMBL405393 SCHEMBL405393 0.44 3/20
SCHEMBL871585 SCHEMBL871585 0.40 2/20
Water Water (SCHEMBL871348) 0.39 2/20
SCHEMBL714334 SCHEMBL714334 0.35 2/20
SCHEMBL229067 SCHEMBL229067 0.67 1/20
SCHEMBL467923 SCHEMBL467923 0.66 1/20
SCHEMBL504093 SCHEMBL504093 0.64 1/20
SCHEMBL240822 SCHEMBL240822 0.62 1/20
SCHEMBL335492 SCHEMBL335492 0.62 1/20
3-Hydroxyphenylacetate 3-Hydroxyphenylacetate (SCHEMBL337470) 0.62 1/20

Clinical trials — most relevant to CTBP2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy. PHASE1/PHASE2RECRUITING
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) PHASE1/PHASE2RECRUITING
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Single-Dose AAV-MECP2 Safety/Tolerability and Efficacy in Rett Syndrome EARLY_PHASE1ACTIVE_NOT_RECRUITING
Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy EARLY_PHASE1RECRUITING
Characterization of Microbiological and Genetic Features in Prostate Cancer and Their Association with Disease Stage nanENROLLING_BY_INVITATION
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
A Prospective Study of Molecular Detection of Salvageable Early Recurrent Nasopharyngeal Carcinoma After Radiotherapy nanCOMPLETED
Genetics and Psychopathology in the 22q11 Deletion Syndrome nanUNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Evaluation of CEMIP in Pancreatic Cancer nanUNKNOWN
Zinc and the Synthesis of Zinc Binding Proteins (Protocol B) nanCOMPLETED
New Genes Involved in Molecular Etiology of Rett Syndrome Through DNA Microarray Comparative Genomic Hybridization nanCOMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins. nanUNKNOWN
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation nanUNKNOWN
Muscle Tissue Bank for Muscular Dystrophy nanCOMPLETED
Immune Cell Response to Stimuli nanRECRUITING
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population nanCOMPLETED
Emotional Regulation in Children With ND: the Role of Genomic Variation, Proteomic Patterns, and Early Experience nanUNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Epidemiological and Genetic Studies of Body Mass Index nanCOMPLETED
Chromosome 5Q Gene Variants and Asthma-Related Traits nanCOMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Genetic Mechanisms of Chronic Obstructive Pulmonary Disease (COPD) nanCOMPLETED
Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CTBP2 binder may also engage these)

ProteinNameSimilarity
Q0VCQ1 — 1.000 Q0VCQ1 →
Q9EQH5 — 1.000 Q9EQH5 →
P56546 — 1.000 P56546 →
Q9W758 — 0.998 Q9W758 →
Q13363 — 0.998 Q13363 →
Q9Z2F5 — 0.997 Q9Z2F5 →
O88712 — 0.997 O88712 →
Q9YHU0 — 0.996 Q9YHU0 →
E9Q4Z2 — 0.976 E9Q4Z2 →
O46036 — 0.975 O46036 →
Q5VV42 — 0.973 Q5VV42 →
Q5E9N5 — 0.971 Q5E9N5 →
O35099 — 0.970 O35099 →
Q641K1 — 0.970 Q641K1 →
ACACB Acetyl-CoA carboxylase 2 0.970 landscape →
Q91WE6 — 0.970 Q91WE6 →
Q9UPW5 — 0.969 Q9UPW5 →
P62205 — 0.969 P62205 →
MAP4K5 Mitogen-activated protein kinase kinase kinase kinase 5 0.968 landscape →
MAP3K5 Mitogen-activated protein kinase kinase kinase 5 0.968 landscape →
Q5IH13 — 0.967 Q5IH13 →
Q8BPM2 — 0.967 Q8BPM2 →
Q5ZKK7 — 0.967 Q5ZKK7 →
Q9WTT2 — 0.967 Q9WTT2 →
P40510 — 0.967 P40510 →
Q60HG1 — 0.967 Q60HG1 →
Q6P4Y0 — 0.966 Q6P4Y0 →
Q1RMT1 — 0.966 Q1RMT1 →
Q9H078 — 0.966 Q9H078 →
G4LTX4 — 0.966 G4LTX4 →